Handelsavisen
prelaunch
Companies Health Care OGN.V
OG
OGN.V TSX Venture Pharmaceuticals

Orogen Royalties Inc

$3,35
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
ROE
Net margin
Debt / equity
Beta
52w range
Volume
Day range
Prev close
$13,53
Open
$13,51
Next earnings
Ex-dividend
TR 1Y
About

Orogen Royalties Inc is a diversified mining company that generates revenue primarily through the extraction and sale of various minerals and metals.

Business. Orogen Royalties Inc (OGN.V) is a diversified mining company operating within the Basic Materials sector. The firm is headquartered in Canada and is primarily listed on the TSX Venture Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification99 %
SectorHealth Care
Industry groupPharmaceuticals
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
not yet wired
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning OGN.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,7 %+1,5 %
    Communication Services+2,2 %−5,5 %+1,5 %
    Energy+0,9 %+5,2 %+0,1 %
    Health Care · THIS SECTOR+0,7 %−0,8 %−0,1 %
    Information Technology+0,2 %+8,1 %−0,5 %
    Consumer Discretionary+0,2 %+8,7 %−0,6 %
    Financials−0,3 %−2,8 %−1,0 %
    Consumer Staples−0,6 %+2,2 %−1,3 %
    Real Estate−0,7 %+10,9 %−1,5 %
    Industrials−1,1 %−0,3 %−1,9 %
    Utilities−1,9 %+28,2 %−2,6 %

    Developing storylines

    No tracked sagas currently linked to OGN.V. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-07-26 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionFederal Reserve rate decision (press conf.)2026-07-29 · US
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Orogen Royalties Inc (OGN.V) is a diversified mining company operating within the Basic Materials sector. The firm is headquartered in Canada and is primarily listed on the TSX Venture Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

    Classification99 %
    SectorHealth Care
    Industry groupPharmaceuticals
    AI synthesis
    GENERATED

    Orogen Royalties Inc maintains a relatively strong liquidity position, with CAD 7,912,000 in cash and equivalents, which provides a buffer against short-term obligations. The company's total liabilities amount to CAD 30,408,140, with long-term debt at CAD 187,690, indicating a low reliance on long-term financing and a manageable debt structure. The operating cash flow of CAD 1,363,910 supports ongoing operations and suggests the company is generating sufficient cash to sustain its activities.

    In terms of profitability, Orogen Royalties Inc reported revenue of CAD 9,600,670, which is a key indicator of its operational performance. While the company's profitability metrics are not explicitly provided, the revenue figure suggests a moderate scale of operations. The company's return on invested capital (ROIC) and other profitability ratios are not available in the current dataset, but the revenue level indicates a need for further analysis to assess its efficiency and returns relative to industry benchmarks.

    The company's revenue is derived from a diversified set of segments and geographic regions, though specific details on revenue concentration are not provided in the available data. This lack of detail makes it difficult to assess the extent of geographic or segment concentration risk. However, the company's classification as a diversified mining entity suggests a broad exposure to various mineral resources and markets.

    Looking ahead, the company's growth trajectory is not explicitly outlined in the available data. The absence of detailed outlook figures for the current and next fiscal years means that the direction and magnitude of revenue growth are uncertain. Historical revenue data is limited to a single period, making it challenging to identify trends or project future performance.

    The risk assessment for Orogen Royalties Inc indicates a low level of liquidity and dilution risk. There are no immediate filing-based liquidity or dilution flags, suggesting that the company is not currently facing significant financial pressures that could impact its operations or shareholder value. The company's low reliance on long-term debt and strong cash reserves further support this assessment.

    Recent events and filings do not show any significant developments that would impact the company's financial position or strategic direction. The absence of notable events in the latest filings suggests a stable operational environment, though this also means there is limited new information to inform future expectations.

    Key takeaways
    • Orogen Royalties Inc maintains a strong liquidity position with CAD 7.9 million in cash and equivalents.
    • The company's total liabilities are CAD 30.4 million, with minimal long-term debt exposure.
    • Revenue of CAD 9.6 million indicates a moderate scale of operations, though detailed profitability metrics are not available.
    • The company is classified as a diversified mining entity, suggesting broad exposure to various mineral resources.
    • No immediate liquidity or dilution risks are flagged, indicating a stable financial position.
    • Recent filings do not show significant events that would impact the company's operations or strategic direction.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $3,35
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    Net cash
    $7.7M
    Current ratio
    Debt / equity
    ROA
    ROE
    Cash conversion
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryPharmaceuticals695,2B node revenueJNJ 13,6%LLY 9,4%MRK 9,3%PFE 9,0%ABBV 8,8%AZN 8,4%BMY 6,9%GSK 6,2%Other 28,3%
    Source: company disclosures · own-taxonomy revenue-covered set · attribution: collision-suspect (indicative)OGN 0,9% · rank #17 of 68

    Business relationships

    Business relationships115 disclosed relationships · 2 types · extracted from filings & disclosures
    Partners1
    MERCK & CO., INC.MRK.OPartner95%Source ↗
    Subsidiaries114
    EX21:00c71704d90cEX21:00c71704d90cSubsidiarie97%
    EX21:0135759e5513EX21:0135759e5513Subsidiarie97%
    EX21:0708351f12a6EX21:0708351f12a6Subsidiarie97%
    EX21:0924fc5e2e98EX21:0924fc5e2e98Subsidiarie97%
    EX21:0aa6a42fd81eEX21:0aa6a42fd81eSubsidiarie97%
    EX21:0afca69ce3f2EX21:0afca69ce3f2Subsidiarie97%
    EX21:0f95cf4662daEX21:0f95cf4662daSubsidiarie97%
    EX21:10e5a6ff4856EX21:10e5a6ff4856Subsidiarie97%
    EX21:13bbfc3f6632EX21:13bbfc3f6632Subsidiarie97%
    EX21:18978e32fb64EX21:18978e32fb64Subsidiarie97%
    EX21:1bf7f37dd9f5EX21:1bf7f37dd9f5Subsidiarie97%
    EX21:1cb4f0287279EX21:1cb4f0287279Subsidiarie97%
    EX21:1e2c71dc9766EX21:1e2c71dc9766Subsidiarie97%
    EX21:1ff933206cf3EX21:1ff933206cf3Subsidiarie97%
    EX21:226ccf24f825EX21:226ccf24f825Subsidiarie97%
    EX21:2453e384f6c8EX21:2453e384f6c8Subsidiarie97%
    EX21:27ea5745d8d9EX21:27ea5745d8d9Subsidiarie97%
    EX21:29612931ef54EX21:29612931ef54Subsidiarie97%
    EX21:2a0512e4cd3dEX21:2a0512e4cd3dSubsidiarie97%
    EX21:2ab5b8c9270aEX21:2ab5b8c9270aSubsidiarie97%
    EX21:2ec2c8fa4152EX21:2ec2c8fa4152Subsidiarie97%
    EX21:2f3199935351EX21:2f3199935351Subsidiarie97%
    EX21:3152731c9541EX21:3152731c9541Subsidiarie97%
    EX21:33a2e9952d9aEX21:33a2e9952d9aSubsidiarie97%
    EX21:359af3ada9b4EX21:359af3ada9b4Subsidiarie97%
    EX21:35f27a3cc590EX21:35f27a3cc590Subsidiarie97%
    EX21:365715331540EX21:365715331540Subsidiarie97%
    EX21:38d229c0f0bdEX21:38d229c0f0bdSubsidiarie97%
    EX21:3c3fc8197ea2EX21:3c3fc8197ea2Subsidiarie97%
    EX21:420102413fe5EX21:420102413fe5Subsidiarie97%
    EX21:43419aee8530EX21:43419aee8530Subsidiarie97%
    EX21:44812d9a2304EX21:44812d9a2304Subsidiarie97%
    EX21:467cb9249d67EX21:467cb9249d67Subsidiarie97%
    EX21:46df3ec164a3EX21:46df3ec164a3Subsidiarie97%
    EX21:46e3bf8a3b6cEX21:46e3bf8a3b6cSubsidiarie97%
    EX21:47abad00d188EX21:47abad00d188Subsidiarie97%
    EX21:4ab9549a1f7eEX21:4ab9549a1f7eSubsidiarie97%
    EX21:4c2b1687b72fEX21:4c2b1687b72fSubsidiarie97%
    EX21:4d078b10442dEX21:4d078b10442dSubsidiarie97%
    EX21:4def41b600ccEX21:4def41b600ccSubsidiarie97%
    EX21:4f22639374c2EX21:4f22639374c2Subsidiarie97%
    EX21:4fd258053600EX21:4fd258053600Subsidiarie97%
    EX21:5432553136dfEX21:5432553136dfSubsidiarie97%
    EX21:56d0db6d9da7EX21:56d0db6d9da7Subsidiarie97%
    EX21:59a21718d7a7EX21:59a21718d7a7Subsidiarie97%
    EX21:5cdf83381a71EX21:5cdf83381a71Subsidiarie97%
    EX21:5ce5af7cf58eEX21:5ce5af7cf58eSubsidiarie97%
    EX21:5ea73e8ef172EX21:5ea73e8ef172Subsidiarie97%
    EX21:60f998f91aecEX21:60f998f91aecSubsidiarie97%
    EX21:694fec38ffe1EX21:694fec38ffe1Subsidiarie97%
    EX21:695f0ccca554EX21:695f0ccca554Subsidiarie97%
    EX21:6d18ccbb35b8EX21:6d18ccbb35b8Subsidiarie97%
    EX21:6e21caef8e8bEX21:6e21caef8e8bSubsidiarie97%
    EX21:727946a771c9EX21:727946a771c9Subsidiarie97%
    EX21:737cac04a197EX21:737cac04a197Subsidiarie97%
    EX21:739f2ff8edd2EX21:739f2ff8edd2Subsidiarie97%
    EX21:74ab160a8da4EX21:74ab160a8da4Subsidiarie97%
    EX21:764c8252e51eEX21:764c8252e51eSubsidiarie97%
    EX21:770bfa3cb914EX21:770bfa3cb914Subsidiarie97%
    EX21:776d6b5f658cEX21:776d6b5f658cSubsidiarie97%
    EX21:788f7d04610dEX21:788f7d04610dSubsidiarie97%
    EX21:79c58632bb9eEX21:79c58632bb9eSubsidiarie97%
    EX21:7d998164b66fEX21:7d998164b66fSubsidiarie97%
    EX21:7e8aba84a8c3EX21:7e8aba84a8c3Subsidiarie97%
    EX21:85840204db41EX21:85840204db41Subsidiarie97%
    EX21:8645a562e28dEX21:8645a562e28dSubsidiarie97%
    EX21:88a246e9a4dcEX21:88a246e9a4dcSubsidiarie97%
    EX21:8d2881a55093EX21:8d2881a55093Subsidiarie97%
    EX21:8ef311e535f2EX21:8ef311e535f2Subsidiarie97%
    EX21:9322c46fa2eaEX21:9322c46fa2eaSubsidiarie97%
    EX21:975186d4d8cbEX21:975186d4d8cbSubsidiarie97%
    EX21:9a0bb6a5e078EX21:9a0bb6a5e078Subsidiarie97%
    EX21:9adc09ac7999EX21:9adc09ac7999Subsidiarie97%
    EX21:9d431d06fa11EX21:9d431d06fa11Subsidiarie97%
    EX21:9ed9056e29a1EX21:9ed9056e29a1Subsidiarie97%
    EX21:a29e55048343EX21:a29e55048343Subsidiarie97%
    EX21:a308c187d472EX21:a308c187d472Subsidiarie97%
    EX21:a8196385166cEX21:a8196385166cSubsidiarie97%
    EX21:a868d3aa2b9eEX21:a868d3aa2b9eSubsidiarie97%
    EX21:ac021d7983b7EX21:ac021d7983b7Subsidiarie97%
    EX21:adee50c624acEX21:adee50c624acSubsidiarie97%
    EX21:aefadc792503EX21:aefadc792503Subsidiarie97%
    EX21:af5e579e30cbEX21:af5e579e30cbSubsidiarie97%
    EX21:b10927b65165EX21:b10927b65165Subsidiarie97%
    EX21:b1b041380ed4EX21:b1b041380ed4Subsidiarie97%
    EX21:b4fd55efd2f5EX21:b4fd55efd2f5Subsidiarie97%
    EX21:b7ce0530cadeEX21:b7ce0530cadeSubsidiarie97%
    EX21:b9f6a81a81aeEX21:b9f6a81a81aeSubsidiarie97%
    EX21:ba09c97951a2EX21:ba09c97951a2Subsidiarie97%
    EX21:bb656a7b9ca7EX21:bb656a7b9ca7Subsidiarie97%
    EX21:c1cc5ca7ec90EX21:c1cc5ca7ec90Subsidiarie97%
    EX21:c351e7ff91d3EX21:c351e7ff91d3Subsidiarie97%
    EX21:cbed531eb5c0EX21:cbed531eb5c0Subsidiarie97%
    EX21:cd080387b463EX21:cd080387b463Subsidiarie97%
    EX21:cf665cfac684EX21:cf665cfac684Subsidiarie97%
    EX21:d80a7429b7d5EX21:d80a7429b7d5Subsidiarie97%
    EX21:d96afe61daafEX21:d96afe61daafSubsidiarie97%
    EX21:d987debf0817EX21:d987debf0817Subsidiarie97%
    EX21:da96e4397b85EX21:da96e4397b85Subsidiarie97%
    EX21:e06a0e1f4d87EX21:e06a0e1f4d87Subsidiarie97%
    EX21:e16e03aaaed9EX21:e16e03aaaed9Subsidiarie97%
    EX21:e355327c0694EX21:e355327c0694Subsidiarie97%
    EX21:e96cd899443fEX21:e96cd899443fSubsidiarie97%
    EX21:edda63a133e9EX21:edda63a133e9Subsidiarie97%
    EX21:ee982d1e19ddEX21:ee982d1e19ddSubsidiarie97%
    EX21:effc66071737EX21:effc66071737Subsidiarie97%
    EX21:f1014cd6dfc8EX21:f1014cd6dfc8Subsidiarie97%
    EX21:f3a5993e4f82EX21:f3a5993e4f82Subsidiarie97%
    EX21:f491be7c491bEX21:f491be7c491bSubsidiarie97%
    EX21:f5dec32f4d46EX21:f5dec32f4d46Subsidiarie97%
    EX21:f6b6eadfc996EX21:f6b6eadfc996Subsidiarie97%
    EX21:f76383ae8c92EX21:f76383ae8c92Subsidiarie97%
    EX21:fcd400caf1acEX21:fcd400caf1acSubsidiarie97%
    EX21:ff8ce9746d36EX21:ff8ce9746d36Subsidiarie97%

    Supply chain

    Vendors → OGN ↔ Partners → Customers · click any node to drill
    VENDORSPARTNERSCUSTOMERSOGNOGNOrogen Royalties Inc115 entitiesMERCK & CO., INC.US
    1 mention in 10-K0 from corporate websites0 from news dispatches
    Updated 2026-06-24

    Peer comparison

    Peer comparison8 peers · vs OGN · multiples and returns
    JN
    JNJ
    Johnson & Johnson
    $259,27
    634,0B USD
    P/E
    23,5x
    +4,5 vs self
    Div yield
    2,0 %
    -0,5 vs self
    ROE
    33,0 %
    +8,1 vs self
    LL
    LLY
    ELI LILLY AND COMPANY
    $1 185,87
    1,06T USD
    P/E
    133,8x
    +114,8 vs self
    Div yield
    0,5 %
    -2,0 vs self
    ROE
    23,7 %
    -1,2 vs self
    MR
    MRK
    MERCK & CO., INC.
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    PF
    PFE
    Pfizer Inc
    $24,58
    140,9B USD
    P/E
    54,9x
    +35,9 vs self
    Div yield
    7,2 %
    +4,7 vs self
    ROE
    3,0 %
    -21,9 vs self
    AB
    ABBV
    Abbvie Inc
    $256,92
    455,8B USD
    P/E
    106,8x
    +87,8 vs self
    Div yield
    2,6 %
    +0,1 vs self
    ROE
    -63,5 %
    -88,4 vs self
    AZ
    AZN
    AZN.L
    $168,01
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    BM
    BMY
    Bristol-myers Squibb Co
    $61,51
    125,9B USD
    P/E
    16,3x
    -2,7 vs self
    Div yield
    4,4 %
    +1,9 vs self
    ROE
    35,1 %
    +10,3 vs self
    GS
    GSK
    Gsk Plc-spon Adr
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    No cohort benchmark data available for this issuer yet.

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    Source documents
    • Orogen Royalties Inc Market data — financials · 2026-05-28

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    OGN.VCanonical
    TSX Venture · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.
    Relationship graph
    OGNMRK.OEX21:00cEX21:013EX21:070EX21:092EX21:0aaEX21:0afEX21:0f9EX21:10eEX21:13bPharmaceutical
    This companySectorPartnersSubsidiaries

    Evidence & claims

    From filings & derived data
    • Revenue (YoY) (2025-12-31 vs 2024-12-31): -2.9%Derived (calculated)
    • Net margin (FY 2025-12-31): 3.0%Derived (calculated)
    • Gross margin (FY 2025-12-31): 53.3%Derived (calculated)
    • Return on equity (FY 2025-12-31): 24.9%Derived (calculated)
    • Return on assets (FY 2025-12-31): 1.5%Derived (calculated)
    • Current ratio (FY 2025-12-31): 1.82xDerived (calculated)
    • Debt-to-equity (FY 2025-12-31): 16.11xDerived (calculated)
    • Capex (YoY) (2025-12-31 vs 2024-12-31): -7.4%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -15.0%Derived (calculated)
    • Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 8.0%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -78.6%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -78.4%Derived (calculated)
    • Long-term debt (YoY) (2025-12-31 vs 2024-12-31): -2.7%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): -78.4%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 59.3%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): -1.8%Derived (calculated)
    • Gross profit (YoY) (2025-12-31 vs 2024-12-31): -10.8%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -25.5%Derived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -4.1%Derived (calculated)
    • Net income (annual): USD 187MSEC XBRL filing
    • Shareholders' equity (annual): USD 752MSEC XBRL filing
    • Total assets (annual): USD 12.87BSEC XBRL filing
    • Pre-tax income (annual): USD 425MSEC XBRL filing
    • EPS (diluted) (annual): USD-PER-SHARES 1SEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-07-28EVENTUpcomingQ2 2026 earnings (expected) estimated date
    2026-07-02 03:51 UTCNEWSOrganon insider buys $353,000 in shares, 51x typical trade size → The unusual open-market purchase signals strong internal conviction in the women's health company, prompting a thesis revision at Handelsavisen.
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)
    2026-06-26 03:13 UTCHOLDERInstitutional holding changed
    2026-06-26 03:13 UTCHOLDER1 institutional position change flagged (1 major)
    2026-06-25 03:10 UTCHOLDERInstitutional holding changed
    2026-06-25 03:10 UTCHOLDER1 institutional position change flagged (1 major)
    2026-06-12 00:00 UTCINSIDER9 insider transactions — 2026-06 9 derivative
    2026-06-12INSIDERPatton Cynthia M acquired 17.9k sh Phantom Stock — Director
    2026-06-12INSIDERSharp Shalini acquired 17.9k sh Phantom Stock — Director
    2026-06-12INSIDERSequeira Ramona acquired 17.9k sh Phantom Stock — Director
    2026-06-12INSIDEROzuah Philip acquired 17.9k sh Phantom Stock — Director
    2026-06-12INSIDERLAZARUS ROCHELLE B acquired 17.9k sh Phantom Stock — Director
    2026-06-12INSIDERESSNER ROBERT acquired 17.9k sh Phantom Stock — Director
    2026-06-12INSIDERLeone Deborah R acquired 17.9k sh Phantom Stock — Director
    2026-06-12INSIDEREzekowitz Alan acquired 17.9k sh Phantom Stock — Director
    2026-06-12INSIDERGayle Helene D acquired 17.9k sh Phantom Stock — Director
    2026-06-11FILINGFORM 8-K →
    2026-05-06 00:00 UTCINSIDER1 insider transaction — 2026-05 · net buy $353k
    2026-05-06INSIDERHolzbaur Lynette bought 26.4k sh — SVP and Corporate Controller ~$353k
    2026-05-04FILING10-Q filing →
    2026-05-01 16:07 UTCFILINGRegulatory filing →
    2026-04-30FILINGFORM 8-K →
    2026-04-27FILING8-K filing →
    2026-04-24FILINGDEF 14A filing →
    2026-03-31 00:00 UTCINSIDER84 insider transactions — 2026-03 · net sell $418k 36 derivative
    2026-03-31INSIDERKarp Daniel transacted 3.6k sh — Executive VP, Corp. Dev. ~$20k
    2026-03-31INSIDERDrinane Juliana Papa transacted 6.4k sh — Interim Head of Mfg & Supply
    2026-03-31INSIDERDrinane Juliana Papa transacted 2.2k sh — Interim Head of Mfg & Supply ~$12k
    2026-03-31INSIDERDrinane Juliana Papa transacted 10.1k sh — Interim Head of Mfg & Supply
    2026-03-31INSIDERDrinane Juliana Papa transacted 3.5k sh — Interim Head of Mfg & Supply ~$20k
    2026-03-31INSIDERArjona Ferreira Juan Camilo transacted 13.4k sh — Head of R&D & CMO
    2026-03-31INSIDERArjona Ferreira Juan Camilo transacted 4.8k sh — Head of R&D & CMO ~$27k
    2026-03-31INSIDERKarp Daniel transacted 11.3k sh — Executive VP, Corp. Dev.
    2026-03-31INSIDERKarp Daniel transacted 6.7k sh — Executive VP, Corp. Dev.
    2026-03-31INSIDERKarp Daniel transacted 2.1k sh — Executive VP, Corp. Dev. ~$12k
    2026-03-31INSIDERStahler Rachel A transacted 6.6k sh — Chief Information Officer
    2026-03-31INSIDERStahler Rachel A transacted 2.2k sh — Chief Information Officer ~$13k
    2026-03-31INSIDERStahler Rachel A transacted 12.3k sh — Chief Information Officer
    Showing the 40 most recent of 64 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-07-26 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage